Vaxart, Inc.: Series B $12.5M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Influenza, X - Toll Receptor, X - Vaccines, XX - CA

Vaxart (San Francisco, CA) a preclinical-stage developer of a platform vaccine technology focusing on oral delivery that leverages an adjuvant based upon a toll-like receptor, closed a $12.5M Series B financing. Participants include Care Capital.

Jun

2009

Opsona Therapeutics, Ltd.: Series B $4.6M

Posted in I - Series B, Q - 2Q09, R - INTERNATIONAL, X - Autoimmune, X - Inflammation, X - Toll Receptor

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $4.6M Series B financing, bringing the total round to $27.5M. Participants include Roche Venture Fund, Enterprise Ireland, Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

Feb

2009

Opsona Therapeutics, Ltd.: Series B $22.9M

Posted in I - Series B, Q - 1Q09, R - INTERNATIONAL, X - Autoimmune, X - Inflammation, X - Toll Receptor

Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $22.9M Series B financing. Participants include Novartis Venture Funds, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.

to top of page...